Related Experiment Video
Updated: Aug 30, 2025
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
Bone-Targeted Delivery of Novokinin as an Alternative Treatment Option for Rheumatoid Arthritis
Arina Ranjit1, Sana Khajeh Pour1, Ali Aghazadeh-Habashi1
1College of Pharmacy, Idaho State University, Pocatello, ID 83209, USA.
Abstract:
Rheumatoid arthritis (RA) is an autoimmune inflammatory bone destructive disorder that is orchestrated by multiple systems in the body, including Renin-Angiotensin System (RAS) and arachidonic acid (ArA) pathway. Current therapeutic options are not highly effective and are associated with severe side effects, including cardiovascular complications. Therefore, new safe and effective disease modulators are seriously needed. In this study, we investigate the anti-inflammatory effects of a synthetic peptide, novokinin, through Angiotensin Type (II) receptor (AT2R). Peptide drugs like novokinin suffer from plasma instability and short half-life. Thus, we developed a novel bone targeting novokinin conjugate (Novo Conj). It uses the bone as a reservoir for sustained release and protection from systemic degradation, improving stability and enhancing pharmacological efficacy. We tested Novo Conj's anti-inflammatory effects in adjuvant-induced arthritis (AIA) rat model to prove our hypothesis by measuring various RAS and ArA pathway components. We observed that inflammation causes a significant imbalance in cardioprotective RAS components like ACE2, AT2R, and Ang 1-7 and increases the ArA inflammatory metabolites like hydroxyeicosatetraenoic acids (HETEs). Treatment with novokinin or Novo Conj restores balance in the RAS and favors the production of different epoxyeicosatrienoic acids (EETs), which are anti-inflammatory mediators. This study demonstrated that the bone-targeted delivery improved the stability and enhanced the anti-inflammatory effects of the parent peptide novokinin in AIA. These observations offer an efficacious alternative therapy for managing RA.
Insights
A novel bone-targeted novokinin conjugate (Novo Conj) effectively reduced inflammation in rheumatoid arthritis (RA) models. This targeted approach improved peptide stability and enhanced anti-inflammatory effects, offering a promising new therapy for RA.
Area of Science:
- Immunology
- Pharmacology
- Biochemistry
Background:
- Rheumatoid arthritis (RA) is a severe autoimmune disorder causing bone destruction, involving the Renin-Angiotensin System (RAS) and arachidonic acid (ArA) pathway.
- Current RA treatments have limited efficacy and significant side effects, necessitating novel therapeutic strategies.
- Novokinin, a synthetic peptide, shows potential anti-inflammatory effects via Angiotensin Type II receptor (AT2R) but lacks stability.
Purpose of the Study:
- To investigate the anti-inflammatory potential of a novel bone-targeted novokinin conjugate (Novo Conj).
- To evaluate the efficacy of Novo Conj in restoring balance within the RAS and ArA pathways in an inflammatory arthritis model.
- To assess the benefits of bone-targeted delivery for improving peptide stability and pharmacological activity.
Main Methods:
- Development of a bone-targeting novokinin conjugate (Novo Conj) for sustained release and protection.
- Utilized an adjuvant-induced arthritis (AIA) rat model to assess anti-inflammatory effects.
- Measured key components of the Renin-Angiotensin System (RAS) and arachidonic acid (ArA) pathway to evaluate treatment efficacy.
Main Results:
- Inflammation in the AIA model significantly disrupted cardioprotective RAS components (ACE2, AT2R, Ang 1-7) and increased inflammatory ArA metabolites (HETEs).
- Treatment with novokinin and Novo Conj restored balance in the RAS.
- Novo Conj treatment promoted the production of anti-inflammatory epoxyeicosatrienoic acids (EETs) and demonstrated enhanced stability and efficacy compared to unconjugated novokinin.
Conclusions:
- Bone-targeted delivery of novokinin (Novo Conj) significantly enhances its stability and anti-inflammatory efficacy in an experimental arthritis model.
- Novo Conj effectively modulates the RAS and ArA pathways, counteracting inflammation and bone destruction associated with RA.
- This study presents Novo Conj as a promising, stable, and efficacious alternative therapeutic approach for managing rheumatoid arthritis.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...